

1 **Neuro-COVID long-haulers exhibit broad dysfunction in T cell memory generation and**
2 **responses to vaccination**

3 Lavanya Visvabharathy^{1**¶}, Barbara Hanson^{1,3}, Zachary Orban¹, Patrick H. Lim¹, Nicole M.
4 Palacio², Rishi Jain¹, Jeffrey R. Clark¹, Edith L. Graham¹ Eric Michael Liotta¹, Pablo Penaloza-
5 MacMaster², Igor J. Koralnik^{1*}

6 ¹Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern
7 University, Chicago IL 60611 USA

8 ²Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern
9 University, Chicago IL 60611 USA

10 ³Rush Medical College, Chicago IL 60612 USA

11

12 *Corresponding authors: Igor J. Koralnik, M.D.: igor.koralnik@northwestern.edu;

13 Lavanya Visvabharathy, Ph.D: lavanya.visvabharathy@northwestern.edu

14 ¶ Lead contact: Lavanya Visvabharathy, Ph.D

15 **Summary**

16 The high prevalence of post-acute sequelae of SARS-CoV-2 infection (PASC) is a significant
17 health concern. In particular, virus-specific immunity in patients who suffer from chronic
18 neurologic symptoms after acute SARS-CoV-2 infection remain poorly understood. Here, we
19 report that Neuro-PASC patients have a specific immunological signature composed of humoral
20 and cellular responses that are biased towards different SARS-CoV-2 structural proteins
21 compared to healthy COVID convalescents, including a significant elevation in Nucleocapsid-
22 specific antibody and T cell responses. Interestingly, the severity of cognitive deficits or quality
23 of life markers in Neuro-PASC patients are associated with reduced effector molecule expression
24 in memory T cells. Furthermore, we demonstrate a sustained elevation in T cell responses to
25 SARS-CoV-2 mRNA vaccines in Neuro-PASC patients compared with healthy COVID
26 convalescents. These data provide a framework for the rational design of predictive biomarkers
27 and therapeutics for long COVID syndrome.

28 **Keywords:** COVID-19 immunity, T cell memory, Neuro-PASC, long COVID, vaccine-induced
29 immunity

30 **Introduction**

31 SARS-CoV-2 is the causative agent of a worldwide pandemic that started in Wuhan,
32 China in December, 2019. There have been more than 240 million cases and over 5 million
33 deaths globally attributable to COVID-19 disease (1). Although highly effective vaccines are
34 now used to prevent severe disease and death caused by SARS-CoV-2, long-term sequelae of
35 SARS-CoV-2 infection are increasingly becoming an important medical concern.

36 SARS-CoV-2 infection can result in a wide spectrum of clinical manifestations ranging
37 from asymptomatic carriage to severe multi-organ dysfunction (2-4), and predictive biomarkers
38 to prognosticate either of these clinical outcomes are currently lacking. Globally, the estimated
39 fatality rate following SARS-CoV-2 infection is approximately 2%, but not all patients recover
40 to their baseline states (5). “Long COVID” affects an estimated 30% of all infected people and
41 includes symptoms persisting more than 28 days after SARS-CoV-2 infection, termed “post-
42 acute sequelae of SARS-CoV-2 infection” or PASC (6, 7). Greater than two-thirds of
43 hospitalized COVID patients experience ongoing fatigue, breathlessness, and psychiatric issues
44 such as post-traumatic stress disorder (PTSD) 4-8 weeks after discharge (8). Although the
45 majority of people with prior SARS-CoV-2 infection experience mild disease not requiring
46 hospitalization, more than half of these individuals have symptoms persisting more than 4
47 months after acute infection (9). Many people who survived Middle-East Respiratory Virus
48 (MERS) and the original SARS-CoV epidemic also experienced PTSD and neurological
49 impairments up to 3.5 years after acute infection (10, 11), suggesting that long-term neurological
50 sequelae are a common consequence of certain coronavirus infections more broadly. Recent
51 studies on recovered COVID-19 patients similarly showed significant cognitive deficits in

52 attention, working memory, and emotional processing months after the resolution of acute
53 infection (12).

54 Numerous studies suggest that T cells are necessary for the clearance of SARS-CoV-2. In
55 particular, CD4⁺ T cell responses directed against the Spike protein were found in 100% of
56 healthy COVID convalescents (13), and virus-specific T cell responses were sub-optimal or
57 impaired in severely ill COVID patients (14). Post-mortem autopsies of COVID patients found
58 innate immune cells but not lymphocytes were enriched in lung infiltrate, and that these patients
59 exhibit impaired germinal center formation in lung draining lymph nodes suggesting a defective
60 T follicular helper cell response in severe COVID (15). Additional studies have shown that CD8⁺
61 T cell depletion after SARS-CoV-2 infection of rhesus macaques impairs anamnestic immune
62 protection after subsequent re-infection (16). However, though prior studies have suggested a
63 role for T cells in protecting against acute SARS-CoV-2 infection, these studies did not include
64 those with lingering PASC. Thus, the contribution of virus-specific T cell responses to the
65 etiology of chronic Neuro-PASC remain poorly understood.

66 Here, we focus on a cohort of mostly non-hospitalized long COVID patients presenting
67 with neurological symptoms (“Neuro-PASC”) who exhibit a reduction in quality of life with
68 regards to cognitive and fatigue parameters (17). Our studies show three critical findings: Firstly,
69 that Neuro-PASC patients exhibit decreased Spike-specific but increased Nucleocapsid- and
70 Membrane-specific T cell responses compared with healthy convalescents. Secondly, that the
71 severity of cognitive deficits and quality of life markers were associated with enhanced cytolytic
72 granule expression in memory T cell subsets. Thirdly, we demonstrate that T cell responses to
73 SARS-CoV-2 vaccination are more robust compared with control groups, but may result in
74 aberrant kinetics. Together, these data suggest wide-scale immunological alterations in Neuro-

- 75 PASC patients, with important implications for both appropriate diagnostic and treatment
- 76 strategies.

77 **Results**

78 *Clinical characteristics of Neuro-PASC patient cohorts*

79 We enrolled a total of 111 participants prior to SARS-CoV-2 vaccination drawn from the
80 Neuro-COVID-19 outpatient clinic at Northwestern Memorial Hospital or from the surrounding
81 Chicago area. This included 56 Neuro-PASC patients (“NP” in figure legends; confirmed RT-
82 PCR+ or anti-SARS-CoV-2 Spike IgG+) meeting Infectious Disease Society of America clinical
83 criteria for COVID-19 starting after February 2020 and had neurologic symptoms lasting at least
84 6 weeks post-infection, as previously reported (17). Among those, 48 (86%) were never
85 hospitalized for pneumonia or hypoxemia. We additionally recruited 24 healthy COVID
86 convalescents without lasting symptoms (RT-PCR+ or seropositive for anti- SARS-CoV-2 Spike
87 RBD IgG, “CC” in figure legends); and 31 healthy controls who were RT-PCR- and
88 seronegative for SARS-CoV-2 Spike-IgG (“HC” in figure legends; study description in Fig. 1A).

89 Neuro-PASC patients displayed a constellation of neurological symptoms similar to those
90 previously reported by our group and in other studies (Fig. 1B). In addition, we utilized
91 standardized methods to quantify their quality of life and cognitive disturbances relative to
92 healthy convalescents. Results from the patient reported outcomes information system
93 (PROMIS-57) survey (18) showed that Neuro-PASC patients scored significantly lower on
94 physical function and higher on anxiety, depression, pain and other metrics compared with
95 COVID convalescent subjects or the national average (Fig. 1C). NIH toolbox tests administered
96 to Neuro-PASC patients assessing their cognitive function (19) found them to have significantly
97 lower T scores in the attention module, which was indicative of cognitive dysfunction relative to
98 the national average (Fig. 1D).

99 *Neuro-PASC is associated with a distinct immunodominance hierarchy.*

100 To measure virus-specific T cell responses in Neuro-PASC patients, we performed IFN- γ
101 and IL-2 ELISPOT. Bulk peripheral blood mononuclear cells (PBMC) from each subject were
102 stimulated with peptide pools derived from the Spike (S), Nucleocapsid (N), or Membrane (M)
103 proteins of SARS-CoV-2 (Fig. S1). IFN- γ^+ and IL-2 $^+$ T cell responses to S sub-pools were
104 similar between Neuro-PASC and COVID convalescent subjects (Fig. 2A-B). However, Neuro-
105 PASC individuals tended to have higher IFN- γ^+ T cells against all N and M peptide pools, while
106 COVID convalescents displayed specificity for different regions of N protein and lower
107 responses against M peptides (Fig. 2C-D), indicative of different immunodominance hierarchies
108 between groups. No significant differences were found in IL-2 production, and healthy controls
109 exhibited some response to N pools likely caused by cross-reactivity with endemic coronaviruses
110 (Fig. 2E-F). Importantly, hospitalization prior to the development of Neuro-PASC did not affect
111 the magnitude of IFN- γ responses to viral proteins (Fig. S2). Though post-hospitalized Neuro-
112 PASC patients trended towards lower IFN- γ^+ T cell responses, these were statistically non-
113 significant. Antibody titers against the Spike receptor-binding domain (RBD) also did not differ
114 between Neuro-PASC and COVID convalescent groups (Fig. 2G).

115 *CD4 $^+$ Tfh cells display opposing reactivity to SARS-CoV-2 S- and N-proteins in Neuro-PASC vs.*
116 *healthy COVID convalescents*

117 RNA-Seq analysis of CD4 $^+$ T cells from hospitalized and non-hospitalized COVID
118 patients showed that severe disease is associated with elevated T follicular helper (Tfh)
119 proportions relative to patients with mild disease (20). We sought to determine whether Tfh
120 responses (see gating scheme in Fig. S3C) could similarly differentiate Neuro-PASC patients
121 from healthy convalescents. Immunophenotyping showed that there were no differences in total

122 percentages of T cell subsets, including Tfh cells, between groups (Fig. S4). The activation-
123 induced marker (AIM) assay measures cytokine-independent, antigen-specific T cell activation
124 and has been previously used to detect TCR-mediated activation of SARS-CoV-2-specific T
125 cells (13, 21) and we used this method to investigate Tfh cell activation. Nucleocapsid-specific
126 CD134⁺CD137⁺ (AIM⁺) Tfh cells were significantly elevated in Neuro-PASC compared with
127 COVID convalescents, while the opposite trend was observed in Spike pool-specific activation
128 (Fig. 3A-B). Interestingly, the magnitude of N-specific Tfh cell activation did not correlate with
129 the time since acute infection in either Neuro-PASC or COVID convalescents (Fig. S5A) despite
130 reports showing that antibody titers against N protein decrease rapidly post-infection (22) which
131 would presumably lead to decreased Nucleocapsid-specific Tfh cell activation over time. Indeed,
132 Nucleocapsid-specific IgG titers were in contrast significantly elevated in Neuro-PASC
133 compared with COVID convalescents (Fig. 3C), consistent with the enhanced Nucleocapsid-
134 specific CD4⁺ Tfh cell activation shown in 3B. Similar to Tfh cells, there was no correlation
135 between anti-N IgG titers and time post-symptom onset for either Neuro-PASC or COVID
136 convalescent subjects (Fig. S5B). Previous studies found that IgG titers against N protein decline
137 to undetectable levels in 40% of COVID convalescents within 4 months (23). We largely did not
138 observe this decline in Neuro-PASC patients despite collecting their blood samples an average of
139 193 days post-symptom onset (Fig. 1B).

140 *CD4⁺ T cell cytokine production and polyfunctionality to SARS-CoV-2 peptides differ in Neuro-* 141 *PASC vs. healthy COVID convalescents*

142 To further probe the effector functions of Nucleocapsid-specific CD4⁺ T cells, we determined
143 whether Neuro-PASC and COVID convalescent subjects had altered patterns of cytokine
144 production after N pool stimulation. CD4⁺ T cells from Neuro-PASC patients expressed lower

145 levels of IL-6 and TNF- α in an antigen-specific manner relative to COVID convalescents
146 following stimulation with Nucleocapsid peptides (Fig. 3D-E). CD4⁺ T cells can also produce
147 cytolytic granules (24, 25), and viral infections can induce expansion of CD4⁺ T effector
148 memory cells that secrete copious amounts of cytolytic granules upon antigen encounter (26).
149 We therefore investigated granzyme, Perforin, IL-6, and TNF- α expression in CD4⁺ T cells
150 following stimulation with Spike peptide pools. Neuro-PASC patients had significant elevations
151 in dual and triple cytokine- and cytolytic granule-producing CD4⁺ T cells after S3/4 pool
152 stimulation, including in granzyme A/B⁺, granzyme-B/IL-6⁺, TNF- α /IL-6⁺, and granzyme A/B-
153 Perforin⁺ CD4⁺ T cells (Fig. 3F). Spike-specific CD4⁺ T cells from Neuro-PASC subjects also
154 demonstrated enhanced polyfunctionality, while COVID convalescents had significantly more
155 CD4⁺ T cells limited to producing granzymes A/B/M after Spike pool stimulation (category 2 in
156 yellow, Fig. 3G). A heatmap quantifying this effect showed that Neuro-PASC CD4⁺ T cells had
157 a 2-fold elevation in granzyme A/B/M, granzyme A/B-Perforin, or granzyme A/B/M-Perforin,
158 while COVID convalescents largely produced only granzyme A/B/M in response to Spike
159 peptides (Fig. 3G-H). This data suggests that cytotoxic responses to Spike protein in CD4⁺ T
160 cells from healthy COVID convalescents significantly differ from those experiencing chronic
161 neurologic symptoms.

162 *CD8⁺ memory T cell functionality in Neuro-PASC patients*

163 CD8⁺ memory T cells are crucial for clearing virally infected cells (27). Memory CD8⁺
164 cells can persist for several years after SARS-CoV infection (28), reflecting their importance in
165 preventing severe recurring disease. However, little is known about how memory CD8⁺ T cells
166 function in Neuro-PASC vs. healthy COVID convalescents. CD8⁺ T effector memory cells
167 (TEM or TEMRA; gating strategy in Fig. S3A) which are poised for rapid cytotoxic function

168 upon antigen re-encounter exhibited significant antigen-driven activation in COVID
169 convalescents but in Neuro-PASC patients (Fig. 4A-B). Total percentages of CD8⁺ TEMRA
170 cells were significantly elevated in Neuro PASC patients (Fig. 4C), but despite their increased
171 numbers, CD8⁺ TEMRA cells were less activated by S3/4 peptides and showed a trend towards
172 decreased activation after N pool stimulation compared with COVID convalescents subjects
173 (Fig. 4D-E).

174 Similarly, antigen stimulation resulted in altered cytokine production in CD8⁺ T cell
175 subsets from Neuro-PASC and COVID convalescents. Effector molecule production in CD8⁺ T
176 cells was similar across groups in the unstimulated condition, despite showing some statistically
177 significant differences in Perforin and granzyme B production (Fig. S6B). However, stimulation
178 with the S3/4 pool induced greater IL-6 production in CD8⁺ TEM from the Neuro-PASC group
179 compared to COVID convalescents (Fig. 4F-G). S3/4 pool stimulation also enhanced production
180 of granzymes A or B and Perforin from CD8⁺ TEMRA cells in the Neuro-PASC group, whereas
181 polyfunctionality in granzyme production was more limited in COVID convalescent subjects
182 (Fig. 4I, J, S6C), demonstrating that CD8⁺ T cell memory subsets have enhanced
183 polyfunctionality in Neuro-PASC patients after antigenic stimulation.

184 *Impaired cognition and decreased quality of life metrics correlate with distinct patterns of*
185 *polyfunctionality in memory T cell subsets*

186 Having shown that Tfh and T cell memory responses differed between subject groups,
187 we next sought to probe whether within-group differences in T cell responses correlated with
188 various clinical measures in Neuro-PASC patients. We found a significant positive correlation
189 between the magnitude of IFN- γ production to N protein and higher pain interference scores
190 (Fig. 5A). There was also a trend towards a positive correlation between high scores for

191 depression and the magnitude of the N-specific T cell response (Fig. 5B). To look at associations
192 between clinical parameters and T cell activation, we separated T scores from NIH Toolbox or
193 PROMIS-57 measurements (Fig. 1C-D) into quartiles and only the lowest and highest groups
194 (Q1 vs. Q4) were used for analysis (Fig. S7A, red boxes). Neuro-PASC subjects reporting high
195 (Q4) pain interference scores produced significantly less granzyme A or B and more IL-6 than
196 those with low scores (Fig. 5C-D) from CD8⁺ T cells after S pool stimulation. Further, patients
197 reporting low depression scores had highly polyfunctional Spike-specific CD8⁺ TEM, while
198 those reporting high levels of depression had TEM producing ~3-fold higher granzymes A, B,
199 and M alone (category 2; Fig. 5E, F). The severity of cognitive impairment could also be
200 significantly correlated with T cell responses. Patients scoring low on executive function tests
201 had CD8⁺ TCM polarized towards granzymes A, B, M and Perforin production, while those with
202 high executive function were biased to produce granzymes A, B, and Perforin (Fig. 5G-H).
203 Similar analyses were performed for other CD8⁺ and CD4⁺ memory T cell subsets, and
204 significant differences by quartile were also found in correlations with depression, processing
205 speed, working memory, and global pain (Fig. S7B-K). These data show that the severity of
206 cognitive deficits or quality of life measures can be significantly correlated with differences in
207 SARS-CoV-2-specific memory T cell function.

208 *SARS-CoV-2 vaccination induces more robust Spike-specific T cell responses in Neuro-PASC*
209 *while displaying aberrant kinetics compared to COVID convalescents*

210 Although prior studies have shown that COVID convalescents develop more potent anti-
211 Spike antibody responses following vaccination relative to uninfected individuals (29, 30), it is
212 unclear whether vaccine-elicited immune responses are impacted by lingering PASC symptoms.
213 We conducted a longitudinal study assessing Spike-specific antibody and T cell responses post-

214 vaccination (study design and patient demographics in Fig. 6A-B). While this study is ongoing,
215 we report data from the first 4 months comparing responses in Neuro-PASC, COVID
216 convalescents, and unexposed healthy control subjects (sample sizes per study visit shown in
217 Fig. S8). The magnitude and kinetics of the T cell response in COVID convalescents and healthy
218 control subjects were similar and peaked at V3. However, Neuro-PASC patients had
219 significantly elevated T cell responses compared with other groups at V2 after the second
220 vaccine dose (Fig. 6C; individual pool data shown in Fig. S9), similar to what was seen with
221 antibody titers at this same timepoint (Fig. 6D). IFN- γ -specific T cell responses remained high at
222 4 months post-vaccination in Neuro-PASC patients while not differing from pre-vaccination
223 levels in both COVID convalescents and unexposed healthy controls. Vaccination also induced
224 robust SARS-CoV-2 Spike RBD IgG titers in all groups tested by 3 weeks post-2nd dose, with
225 the highest titers found in Neuro-PASC patients. Antibody titers declined to similar levels in all
226 groups by 3 months post-1st dose, but trended higher in Neuro-PASC than in healthy control
227 subjects at visit 4 (Fig. 6D). To our knowledge, these are the first data that longitudinally
228 compare the T cell response to vaccination in Neuro-PASC patients with healthy COVID
229 convalescents and unexposed individuals.

230 Overall, our study demonstrates that Neuro-PASC patients have elevated IFN- γ responses
231 to internal proteins of SARS-CoV-2 (N and M proteins), enhanced activation of Tfh cells linked
232 to increased anti-Nucleocapsid antibody production, but impaired CD8⁺ T cell memory
233 compared with healthy COVID convalescents. There were also correlations between the severity
234 of cognitive deficits or quality of life impairments and increased cytolytic granule production.
235 Importantly, vaccination resulted in robust increases Spike-specific T cell responses in Neuro-
236 PASC patients vs. all other groups, regardless of prior COVID exposure, while also displaying

237 aberrant kinetics. Together, we show that Neuro-PASC patients exhibit distinct activation and
238 effector signatures in multiple aspects of the memory T cell response which may inform
239 treatment options down the line.

240

241 **Discussion**

242 COVID-19 is well-recognized as a multi-organ disease with long-term sequelae
243 associated with neurological dysfunction. PASC has been reported in up to 87% of those
244 hospitalized with SARS-CoV-2 pneumonia and in 30% of those with mild disease who do not
245 require hospitalization (31-33). Long-term sequelae after other coronavirus infections can persist
246 for years (10); therefore, it is important to specifically characterize SARS-CoV-2-specific
247 immune responses in long COVID patients. Most studies on effector and memory T cell
248 responses to SARS-CoV-2 have focused on acute infection or healthy convalescents as opposed
249 to those with long COVID (34-36). We aimed to fill this knowledge gap and determine whether
250 and how T cell phenotype and function differ in patients with Neuro-PASC and healthy COVID-
251 19 convalescents.

252 Clinically, neuro-PASC resembles myalgic encephalomyelitis/chronic fatigue syndrome
253 (ME/CFS), which many patients report as a post-viral infectious complication (37). The causes
254 of ME/CFS remain elusive, and the underlying mechanisms of Neuro-PASC remain similarly
255 unknown. One hypothesis for the etiology of Neuro-PASC is that symptoms could be caused by
256 direct infection of the CNS. SARS-CoV-2 gains entry into the central nervous system through
257 the olfactory bulb and has been shown to infect neurons in vitro, which is supported by findings
258 of viral protein expression in cortical neurons from post-mortem autopsies and presence of virus
259 in the brain in mouse models of infection (38-40). However, another study was unable to find
260 any evidence of SARS-CoV-2 in the brains of 4 patients with neurological symptoms during
261 acute infection (41), suggesting that infection of the nervous system may be transient. Further
262 studies in acutely infected Neuro-COVID patients did not find any SARS-CoV-2 RNA present in
263 the CSF, though they did identify enhanced presence of exhausted T cells and dedifferentiated

264 monocytes (42). However, all of these prior studies were conducted on patients with acute
265 SARS-CoV-2 infection as opposed to Neuro-PASC, and thus mechanisms for neurological
266 dysfunction may differ. As lumbar punctures or brain biopsies are not indicated in neuro-PASC
267 outpatients, reproducing the above study results in outpatient populations is not possible.
268 Additional hypotheses for Neuro-PASC pathogenesis include a contribution of autoimmune
269 mechanisms which is suggested by the skewed ratio of females to males affected, similar to that
270 seen in rheumatoid arthritis or systemic lupus erythematosus (43, 44), as well as the possibility
271 of persistent SARS-CoV-2 infection in the periphery (45). Much of our findings on the SARS-
272 CoV-2 T cell response in neuro-PASC patients supports this latter hypothesis.

273 Ag-specific IFN- γ and IL-2 production was similar between Neuro-PASC and COVID
274 convalescent groups in response to stimulation by different SARS-CoV-2 Spike peptide pools
275 (Fig. 2A-B). However, T cells from Neuro-PASC patients retained high IFN- γ responses to all
276 N- and M-peptide pools tested, while COVID convalescents had a reactivity limited to N1 and
277 N2 peptide pools with little IFN- γ production in response to M pools (Fig. 2C-D). The presence
278 of an immunodominance hierarchy in COVID convalescents is the expected outcome of an
279 effective memory response to SARS-CoV-2 infection. Studies have shown that while a primary
280 CD4⁺ or CD8⁺ T cell response to influenza A or LCMV infection is highly diverse and contains
281 T cells reactive to many viral proteins and epitopes, the memory response preferentially contains
282 T cells responding to specific immunodominant viral antigens (46, 47). This effect is more
283 pronounced in the CD8⁺ T cell compartment where memory responses are dependent on the
284 ability of dendritic cells to present viral antigen (48) or on antigen availability (49). The evident
285 lack of a narrow and targeted IFN- γ response to N- and M-peptides in Neuro-PASC patients thus
286 suggests that they are unable to effectively generate a memory response to SARS-CoV-2.

287 Though there were no differences observed in the magnitude or specificity of the IFN- γ response
288 to SARS-CoV-2 Spike peptides, this is somewhat expected as memory T cell responses to Spike
289 protein remain diverse after both infection (13) and vaccination (50). It is additionally not
290 surprising that differences in reactivity were observed for IFN- γ and not IL-2 T cell responses
291 between Neuro-PASC and COVID convalescent groups (Fig. 2B, E-F). Studies have
292 demonstrated that while Ag-specific T cells produce IL-2 as a proliferation factor, IFN- γ
293 production is largely confined to the memory T cell compartment (51), which is largely where
294 we see differences in activation and reactivity between groups (Fig. 4).

295 Antibody production is a key outcome measure after SARS-CoV-2 infection, and Tfh cell
296 activation can inform the effectiveness of an antibody response. Stimulation with SARS-CoV-2
297 N peptides activated Tfh cells in Neuro-PASC but not COVID convalescent subjects (Fig. 3A-
298 B). Tfh cell activation is crucial to the establishment of germinal centers in secondary lymphoid
299 organs, ultimately resulting in B cell maturation into long-lived plasma cells that can
300 continuously produce class-switched, high-affinity antibodies (52). The magnitude of the Tfh
301 cell response is dependent on the amount of antigen available and directly correlates with the
302 magnitude of the B cell response (53). Indeed, the same Neuro-PASC patients with high N-
303 specific Tfh cell activation also displayed anti-N IgG titers significantly greater than COVID
304 convalescent subjects (Fig. 3C) despite the fact that we obtained their samples more than 6
305 months on average after acute infection. Altogether, these findings are consistent with the
306 potential existence of a persisting Nucleocapsid antigen reservoir resulting in enhanced N-
307 specific Tfh cell activation in Neuro-PASC patients. Clinical reports have identified cases of
308 persistent SARS-CoV-2 infection in the nasopharynx lasting up to 63 days (54) and many
309 patients re-tested RT-PCR+ for SARS-CoV-2 up to 38 days post-discharge (55). The

310 nasopharynx is not the only possible testing site, however, as there are numerous studies showing
311 that infectious SARS-CoV-2 particles can be detected in fecal matter and can persist for up to 70
312 days post-symptom onset (56, 57). Gastrointestinal symptoms also did not have to be present in
313 order to test RT-PCR+ for SARS-CoV-2 in stool samples (58). Thus, it is possible that the gut
314 may also act as a reservoir for persistent SARS-CoV-2 infection which leads to aberrant T cell
315 responses and the development of Neuro-PASC.

316 Effective generation of T cell memory responses is crucial to protect against future
317 infections with the same pathogen. CD8⁺ TEM cells from COVID convalescents exhibited
318 normal patterns of activation to S, N, and M peptides while Neuro-PASC patients displayed very
319 little TEM activation (Fig. 4A-B), suggestive of CD8 memory T cell dysfunction. Studies on
320 convalescents from the original SARS-CoV epidemic found that the majority of Ag-specific
321 CD8⁺ memory T cells were TEM, and these persisted up to 4 years after infection (59).
322 Resolution of acute infection is a necessary precondition for the development and maintenance
323 of memory T cells. In particular, protracted viral infections favor the generation of short-lived
324 effector cells and exhausted T cells (60, 61), which is why chronic infections often limit the
325 formation and/or function of memory T cells (62). This has been shown with chronic LCMV
326 infection in mice, which induced aberrantly functioning Ag-specific memory CD8⁺ T cells
327 requiring the presence of viral peptide rather than simply the homeostatic cytokines IL-7 and IL-
328 15 to proliferate (63, 64). The inability of CD8⁺ TEM to become activated by antigenic
329 stimulation in Neuro-PASC patients is thus suggestive of a chronic infection state wherein viral
330 antigen can persist but limits the formation of CD8⁺ T cell memory.

331 Further providing support to the chronic infection hypothesis in Neuro-PASC patients,
332 there was a significant elevation in CD8⁺ TEMRA cells in Neuro-PASC patients over COVID

333 convalescent or unexposed healthy control groups (Fig. 4C). CD8⁺ TEMRA cells are terminally
334 differentiated memory T cells that do not traffic through secondary lymphoid organs, and their
335 induction during viral infection can be protective (65). Yet, they have also been shown to
336 accumulate during persistent viral infections and contribute to immunosenescence (66). In
337 contrast to increased cell numbers, CD8⁺ TEMRA reactivity to Spike peptides was decreased in
338 Neuro-PASC patients over COVID convalescents (Fig. 4E). Functionally, the polarization in
339 granzyme production in S3/4-specific CD8⁺ TEMRA cells from COVID convalescents (Fig. 4J)
340 suggests higher cytotoxic capacity compared with Neuro-PASC patients and coincides with their
341 higher activation state in Fig. 4E. Ag-specific CD8⁺ TEMRA cells are both expanded and
342 functionally active in people with significant anti-Dengue virus immunity, and this phenotype is
343 seen as a goal for vaccine-induced protection (65). We propose that CD8⁺ TEMRA cells are
344 more expanded but less functionally active in Neuro-PASC patients compared with healthy
345 convalescents as a consequence of inappropriate CD8⁺ T cell memory formation.

346 We also showed that CD8⁺ T effector memory cells from Neuro-PASC subjects produced
347 considerable amounts of IL-6 in response to Spike peptides, while COVID convalescents tended
348 towards enhanced TNF- α production (Fig. 4F-H). Vaccination against the intracellular pathogen
349 *Shigella flexneri* showed that polyfunctional TNF- α -producing CD8⁺ TEM were an important
350 correlate of protection (67). Despite multiple reports indicating that enhanced TNF- α production
351 is correlated with worse COVID-19 outcomes (68-70), we speculate that Ag-specific TNF- α
352 production is protective in our model system because we are looking at chronically and not
353 acutely infected Neuro-PASC patients. In contrast, IL-6 is known to suppress T_H1 differentiation
354 (71) and promoted pathogen survival and exacerbated clinical disease during the original SARS-
355 CoV infection (72). Indeed, studies in severely ill, hospitalized COVID-19 patients demonstrated

356 that high serum levels of IL-6 significantly correlated with poor clinical outcome (34). These
357 data suggest a role for enhanced IL-6 production by CD8⁺ TEM in the pathogenesis of Neuro-
358 PASC, and open new avenues of research for the treatment of long COVID through limiting IL-6
359 activity.

360 Clinically, Neuro-PASC patients reported significantly elevated levels of anxiety,
361 depression, fatigue, sleep disturbance and pain as well as decreased physical function compared
362 with healthy convalescents (Fig. 1C). The severity of these deficits was highly correlated with
363 Ag-specific enhancements in polyfunctionality and decreases in polarization of various memory
364 T cell subsets (Fig. 5, S7). It is possible that T cell function contributes to the genesis and
365 persistence of some of these symptoms. Studies in rodents have shown that T cell activation and
366 function can affect the severity of pain and analgesia (73, 74). Indeed, pain is a common
367 hallmark of chronic viral infection (75) and recognized among post-COVID sequelae (76); it
368 might follow then that aberrant T cell activation can associate with high pain scores.
369 Additionally, reports have shown that transcriptional programs in immunity and inflammation
370 were differentially regulated in CD4⁺ T cells from patients with depression compared with
371 healthy controls (77). T_{reg} cells may also decrease depressive behavior through negative
372 regulation of inflammation (78), and Neuro-PASC patients do display elevated T_H1-type
373 cytokine production to S pool stimulation compared with healthy controls (Fig. 2, 6) while not
374 displaying any compensatory upregulation in T_{reg} total numbers or function (data not shown). T
375 cell-derived cytokines can also impact learning and memory. Studies in mouse models of West
376 Nile and Zika viral encephalitis have demonstrated that IFN- γ production from CD8⁺ T cells in
377 the brain is responsible for neuronal apoptosis and spatial learning deficits (79). Thus, there is a
378 precedent for correlating T cell function with cognitive deficits, pain, or depression. Ag-specific

379 cytokine signatures associated with the severity of cognitive and quality of life deficits in Neuro-
380 PASC patients may therefore provide some predictive value in terms of clinical outcomes.

381 Preliminary reports showed that the Pfizer mRNA vaccine elicits a T cell response 7 days
382 after completion of the full prime-boost protocol (80) and induces CD8⁺ memory T cell
383 activation (81), but until our studies there has been no data on longitudinal T cell responses
384 primed by vaccination and how these vary between groups with different types of prior SARS-
385 CoV-2 exposure. Our results demonstrate for the first time that vaccine-elicited immune
386 responses are significantly divergent in Neuro-PASC versus healthy COVID convalescents (Fig.
387 6C). The magnitude of Spike-specific IFN- γ production by T cells remained high in Neuro-
388 PASC patients out to 4 months post-vaccination while not significantly higher than pre-
389 vaccination levels in COVID convalescents and healthy controls along the same timeline (Fig.
390 6C). Neuro-PASC patients also demonstrated higher antibody titers after receiving the second
391 dose of the vaccine compared with other groups, though titers were similar in all groups at 11-15
392 weeks post-1st dose (Fig. 6D). Interestingly, there was significant decline in Spike-specific IFN- γ
393 responses in Neuro-PASC patients between weeks 6 and 10 post-first dose before stabilizing at
394 week 15 (visit 4). We speculate that vaccination may induce a short-lasting increase in the
395 effector T cell response at 6 weeks post-1st dose before contracting to baseline levels at 10
396 weeks. However, IFN- γ ⁺ T cell responses continue to remain elevated through 15 weeks in
397 Neuro-PASC patients, unlike COVID convalescents or healthy controls, possibly due to
398 persistent stimulation with Spike protein antigens which may not be present in other groups.

399 These data suggest that the mRNA vaccines do not induce robust long-term T cell
400 responses in many individuals, regardless of prior COVID exposure, if they are not Neuro-PASC
401 patients. Yet, despite vaccines enhancing Spike-specific IFN- γ production in Neuro-PASC T

402 cells, the fact that these responses continue to increase rather than decline at 15 weeks post-
403 vaccination suggests that Neuro-PASC patients may still have an active SARS-CoV-2 infection
404 or a persistent antigen reservoir rather than developing a robust T cell memory response.
405 Therefore, it is possible that alternate SARS-CoV-2 vaccines that induce long-lasting memory T
406 cell responses in previously unexposed individuals as well as healthy COVID convalescents are
407 needed in order to mediate long-term protection from infection. Conversely, vaccination
408 strategies may need to be more fully evaluated for long COVID patients who might have a
409 persistent infection as they may be less effective in the absence of viral clearance. Indeed,
410 current clinical guidance from the CDC recommends that vaccination be delayed until 3 months
411 after acute infection in unvaccinated COVID convalescents. Thus, determinants of vaccine
412 efficacy that include measurement of T cell memory induction should be carefully considered.
413 Together, these data show that enhanced Tfh responses, broad scale dysfunction in CD8⁺ T cell
414 memory generation and aberrant T cell responses to vaccination are hallmarks of Neuro-PASC
415 and require further study to inform treatment and vaccination strategies across the population.

416 **Limitations of study**

417 One limitation of our study is the relatively small sample size of unvaccinated neuro-
418 PASC patients. This was due to the wide implementation of SARS-CoV-2 vaccines in Chicago
419 area soon after beginning study enrollment. Another limitation was not being able to control for
420 time of sample collection with respect to date of COVID-19 symptom onset. As it is possible that
421 neuro-PASC could be the result of a persistent infection, further investigations would require
422 testing of potential cryptic reservoirs, including stool samples from Neuro-PASC patients.

423 **Materials and Methods**

424 *Ethics Statement*

425 This study was approved by the Northwestern University Institutional Review Board (Koralnik
426 Lab, IRB STU00212583). Informed consent was obtained from all enrolled participants. Samples
427 were de-identified before banking.

428 *Study participants, NIH Toolbox, and PROMIS-57 data collection*

429 We enrolled consenting unvaccinated adult outpatients seen in the Neuro-PASC-19 clinic at
430 Northwestern Memorial Hospital from September 2020-June 2021, including 56 Neuro-PASC
431 patients with documented PCR+ or seropositive IgG results for SARS-CoV-2. In parallel, we
432 recruited 24 unvaccinated healthy COVID convalescents from the surrounding community who
433 tested PCR+ for SARS-CoV-2 but had no lingering neurological symptoms and 31 healthy
434 controls who tested PCR- for SARS-CoV-2 and were also seronegative for IgG against SARS-
435 CoV-2 Spike RBD. All study subjects remained living throughout the period of observation.
436 Heparinized blood samples were collected one time from each subject at an average of 155-315
437 days post-symptom onset (as in Fig. 1B). Other demographic information is contained in Fig. 1B.
438 Neuro-PASC patients completed a cognitive function evaluation in the clinic coincident or near
439 the date of their blood sample acquisition with the National Institutes of Health (NIH) Toolbox
440 v2.1 instrument, including assessments of: processing speed (pattern comparison processing
441 speed test); attention and executive memory (inhibitory control and attention test); executive
442 function (dimensional change card sort test); and working memory (list sorting working memory
443 test) (19, 82). PROMIS-57 was administered to Neuro-PASC and COVID convalescent subjects
444 an average of 72 days post-sample collection. Both PROMIS-57 and NIH Toolbox results are

445 expressed as T-scores adjusted for age, education, gender, and race/ethnicity with a score of 50
446 representing the normative mean/median of the US reference population with a standard
447 deviation of 10. Lower cognition T-scores indicate worse performance while higher fatigue,
448 depression, anxiety, or pain interference T-scores indicate greater symptom severity.

449 *PBMC and plasma collection*

450 30mL of venous blood from study volunteers was collected in blood collection tubes containing
451 sodium heparin from BD Biosciences. Whole blood was layered on top of 15mL of Histopaque
452 1077 (Sigma-Aldrich) in 50mL Leucosep blood separation tubes (Greiner Bio-One) and spun at
453 1000g for 18min at RT. Plasma was collected and stored at -80°C. The PBMC layer was
454 collected and washed 2x in sterile PBS before red blood cell lysis with ACK buffer (Quality
455 Biologicals). PBMCs were used in assays either immediately or frozen down for use in the near
456 term.

457 *SARS-CoV-2 peptide antigens*

458 All S, N and M peptide arrays used in ELISPOT and flow cytometry studies were obtained from
459 BEI Resources, NIAID, NIH: Peptide Array, SARS-Related Coronavirus 2 Spike (S) Protein;
460 NR-52402, Nucleocapsid (N) Protein, NR-52404; Membrane (M) Protein, NR-52403. The S
461 peptide array consisted of 181 peptides of 13-17aa in length and split into 6 sub-pools (S1-S6)
462 containing 30-31 peptides each. The N peptide array consisted of 59 peptides of 13-17aa each
463 split into 3 sub-pools containing 29-30 peptides each. The M peptide array consisted of 31
464 peptides of 12-17aa and split into 3 sub-pools of 10-11 peptides each (Fig. S1). All peptides were
465 dissolved in either sterile H₂O or 50% sterile H₂O-DMSO up to 1mL for a universal 1mg/mL
466 stock concentration. Peptides were used at a final concentration at 2µg/mL in all assays.

467 *IgG Spike RBD and Nucleocapsid ELISA*

468 Antigen-specific total antibody titers were measured by ELISA as described previously (Dangi et
469 al., 2020; Palacio et al., 2020). In brief, 96-well flat-bottom MaxiSorp plates (Thermo Scientific)
470 were coated with 1 µg/ml of Spike RBD for 48 hr at 4°C. Plates were washed three times with
471 wash buffer (PBS + 0.05% Tween 20). Blocking was performed with blocking solution (PBS +
472 0.05% Tween 20 + 2% bovine serum albumin), for 4 hr at room temperature. 6 µl of sera was
473 added to 144 µl of blocking solution in the first column of the plate, 1:3 serial dilutions were
474 performed until row 12 for each sample, and plates were incubated for 60 min at room
475 temperature. Plates were washed three times with wash buffer followed by addition of secondary
476 antibody conjugated to horseradish peroxidase, goat anti-human IgG (H + L) (Jackson
477 ImmunoResearch) diluted in blocking solution (1:1000) and 100 µl/well was added and
478 incubated for 60 min at room temperature. After washing plates three times with wash buffer,
479 100 µl/well of Sure Blue substrate (SeraCare) was added for 1 min. Reaction was stopped using
480 100 µl/well of KPL TMB Stop Solution (SeraCare). Absorbance was measured at 450 nm using
481 a Spectramax Plus 384 (Molecular Devices). SARS-CoV-2 RBD and N proteins used for ELISA
482 were produced at the Northwestern Recombinant Protein Production Core by Dr. Sergii
483 Pshenychnyi using plasmids that were produced under HHSN272201400008C and obtained from
484 BEI Resources, NIAID, NIH: Vector pCAGGS containing the SARS-related coronavirus 2,
485 Wuhan-Hu-1 spike glycoprotein gene (soluble, stabilized), NR-52394 and receptor binding
486 domain (RBD), NR-52309, nucleocapsid gene NR-53507.

487 *Cell stimulation and IFN-γ/IL-2 ELISPOT*

488 Multiscreen-IP plates (Millipore-Sigma) were coated overnight at 4°C with 2µg/mL anti-IFN-γ
489 (clone 1-D1K, Mabtech) or 5µg/mL anti-IL-2 (clone MT2A91/2C95, Mabtech), washed with

490 sterile PBS, and blocked with complete RPMI-10% FBS. PBMC isolated from Neuro-PASC,
491 COVID convalescent, and healthy control subjects were used either freshly isolated or after
492 thawing and resting overnight in media containing 10ng/ μ L recombinant human IL-15
493 (Peprotech) at 37°C, 5% CO₂. Cells were then plated at a concentration of 2.5x10⁵ cells/well in
494 100 μ L of media and stimulated with the indicated antigen mixtures from SARS-CoV-2 at a
495 concentration of 2 μ g/mL in complete RPMI medium containing 5% human AB serum (Sigma-
496 Aldrich) and 5ng/mL IL-15. Plates were incubated at 37°C, 5% CO₂ for 20h and washed 5x with
497 dH₂O and PBS-0.05% Tween-20 (PBS-T). 2 μ g/mL biotinylated IFN- γ (clone 7-B6-1, Mabtech)
498 or 5 μ g/mL IL-2 (clone MT8G10, Mabtech) diluted in PBS-10% FBS (PBS-F) was added to the
499 respective wells and plates were incubated for 1.5h at RT. Plates were subsequently incubated
500 for 40 minutes at RT in streptavidin-alkaline phosphatase in PBS-F (Jackson ImmunoResearch)
501 was added after washing plates 5x in PBS-T. ELISPOT plates were developed using an Alkaline
502 Phosphatase Conjugate Substrate Kit according to manufacturer's instructions (Bio-Rad
503 Laboratories, Carlsbad, CA). IFN- γ or IL-2-producing cells were quantified using an
504 ImmunoSpot reader (Cellular Technologies, Ltd., Shaker Heights, OH).

505 *Antibodies and Flow Cytometry*

506 Fresh or frozen PBMCs isolated from the indicated patient groups were stimulated with antigen
507 mixtures as above for 20-22h at 37°C, 5% CO₂. For intracellular staining and cytokine detection,
508 the Brefeldin-A Golgi plug (Biolegend) was added at a 1:1000 concentration 2 hours after
509 antigenic stimulation commenced. Cells were washed with PBS-1% BSA after incubation and
510 incubated with the indicated antibodies for surface phenotyping by AIM assay or for intracellular
511 cytokine staining (ICS; antibodies used described in Supplemental Table 1). Cells from each
512 subject were left unstimulated in medium containing 5ng/mL IL-15 ("background") or

513 stimulated in the presence of the indicated antigens. Fixation and permeabilization was
514 performed using Cytofix/Cytoperm (BD Biosciences). Surface staining was done in the dark at
515 4°C for 30 minutes, while ICS was done in the dark at RT for 45 minutes. Flow cytometry was
516 conducted on $2-5 \times 10^5$ cells per condition. Data was acquired on a BD FACSymphony Spectral
517 analyzer and analyzed using FlowJo v10 (BD Biosciences) and SPICE-Pestle (83).

518 *Quantification and Statistical Analysis*

519 Statistical tests to determine significance are described in figure legends and conducted largely in
520 Prism (GraphPad). For pie graphs or heatmaps generated using SPICE analysis, statistics were
521 determined by Permutation test following unstimulated background subtraction, with additional
522 thresholding of 0.03% to account for noise, using SPICE-Pestle. *P*-values lower than 0.05 were
523 considered statistically significant. Quantile stratification was performed within group for Neuro-
524 PASC cohort. Clinical data were collected and managed using REDCap electronic data capture
525 tools hosted at Northwestern University Feinberg School of Medicine (84). REDCap (Research
526 Electronic Data Capture) is a secure, web-based software platform designed to support data
527 capture for research studies, providing 1) an intuitive interface for validated data capture; 2)
528 audit trails for tracking data manipulation and export procedures; 3) automated export procedures
529 for seamless data downloads to common statistical packages; and 4) procedures for data
530 integration and interoperability with external sources.

531 **Acknowledgements**

532 We would like to thank the Flow Cytometry Core Facility at the Robert H. Lurie Comprehensive
533 Cancer Center at Northwestern University supported by Cancer Center Support Grant (NCI
534 CA060553) for their assistance in optimizing antibody panels and help with flow cytometry
535 instrumentation. L.V. was supported by a T32 grant T32AR007611 from the Department of
536 Rheumatology, Northwestern University Feinberg School of Medicine. P.P.M. is supported by a
537 grant from the Emerging and Re-Emerging Pathogens Program (EREPP) at Northwestern
538 University, and a grant from the National Institute on Drug Abuse (NIDA, DP2DA051912).

539

540 **Author Contributions**

541 Conceptualization L.V. P.P.M. and I.K.; Investigation L.V., B.H., Z.O., P.H.L, and N.P.; Formal
542 Analysis L.V., B.H., E.M.L., P.P.M. and N.P.; Resources L.V., P.P.M., I.K., Data Curation L.V.,
543 E.G., J.R.C.; Writing L.V. with feedback from all authors; Supervision L.V., P.P.M and I.K.;

544 Project Administration L.V.; Funding Acquisition L.V., P.P.M, and I.K.

545

546 **Declaration of Interests**

547 The authors declare no competing interests.

548

549

550

551 **References**

- 552 1. J. C. R. Center. (Johns Hopkins University of Medicine, Baltimore, MD, 2021), vol.
553 2021.
- 554 2. A. Syed, A. Khan, F. Gosai, A. Asif, S. Dhillon, Gastrointestinal pathophysiology of
555 SARS-CoV2 - a literature review. *J Community Hosp Intern Med Perspect* **10**, 523-528
556 (2020).
- 557 3. C. Liguori *et al.*, Subjective neurological symptoms frequently occur in patients with
558 SARS-CoV2 infection. *Brain Behav Immun* **88**, 11-16 (2020).
- 559 4. Y. C. Li, W. Z. Bai, T. Hashikawa, The neuroinvasive potential of SARS-CoV2 may play
560 a role in the respiratory failure of COVID-19 patients. *J Med Virol* **92**, 552-555 (2020).
- 561 5. V. Higgins, D. Sohaei, E. P. Diamandis, I. Prassas, COVID-19: from an acute to chronic
562 disease? Potential long-term health consequences. *Crit Rev Clin Lab Sci*, 1-23 (2020).
- 563 6. E. Ladds *et al.*, Persistent symptoms after Covid-19: qualitative study of 114 "long
564 Covid" patients and draft quality principles for services. *BMC Health Serv Res* **20**, 1144
565 (2020).
- 566 7. S. Vekar, M. Boushra, P. Ntiamoah, M. Biehl, Post-acute sequelae of SARS-CoV-2
567 infection: Caring for the 'long-haulers'. *Cleve Clin J Med* **88**, 267-272 (2021).
- 568 8. S. J. Halpin *et al.*, Postdischarge symptoms and rehabilitation needs in survivors of
569 COVID-19 infection: A cross-sectional evaluation. *J Med Virol* **93**, 1013-1022 (2021).
- 570 9. M. S. Petersen *et al.*, Long COVID in the Faroe Islands - a longitudinal study among
571 non-hospitalized patients. *Clin Infect Dis*, (2020).
- 572 10. H. Ahmed *et al.*, Long-term clinical outcomes in survivors of severe acute respiratory
573 syndrome and Middle East respiratory syndrome coronavirus outbreaks after

- 574 hospitalisation or ICU admission: A systematic review and meta-analysis. *J Rehabil Med*
575 **52**, jrm00063 (2020).
- 576 11. M. H. Lam *et al.*, Mental morbidities and chronic fatigue in severe acute respiratory
577 syndrome survivors: long-term follow-up. *Arch Intern Med* **169**, 2142-2147 (2009).
- 578 12. A. Hampshire, Trender W., Chamberlain SR, Jolly AE, Grant JE, Patrick F, Mazibuko N,
579 Williams S, Barnaby JM, Hellyer H, Mehta MA., Cognitive deficits in people who have
580 recovered from COVID-19. *EClinicalMedicine*, (2021).
- 581 13. A. Grifoni *et al.*, Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans
582 with COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501 e1415 (2020).
- 583 14. S. M. Toor, R. Saleh, V. Sasidharan Nair, R. Z. Taha, E. Elkord, T-cell responses and
584 therapies against SARS-CoV-2 infection. *Immunology* **162**, 30-43 (2021).
- 585 15. Y. Q. Duan *et al.*, Deficiency of Tfh Cells and Germinal Center in Deceased COVID-19
586 Patients. *Curr Med Sci* **40**, 618-624 (2020).
- 587 16. K. McMahan *et al.*, Correlates of protection against SARS-CoV-2 in rhesus macaques.
588 *Nature* **590**, 630-634 (2021).
- 589 17. E. L. Graham *et al.*, Persistent neurologic symptoms and cognitive dysfunction in non-
590 hospitalized Covid-19 "long haulers". *Ann Clin Transl Neurol* **8**, 1073-1085 (2021).
- 591 18. E. Tang *et al.*, Validation of the Patient-Reported Outcomes Measurement Information
592 System (PROMIS)-57 and -29 item short forms among kidney transplant recipients. *Qual*
593 *Life Res* **28**, 815-827 (2019).
- 594 19. S. Weintraub *et al.*, Cognition assessment using the NIH Toolbox. *Neurology* **80**, S54-64
595 (2013).

- 596 20. B. J. Meckiff *et al.*, Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive
597 CD4(+) T Cells in COVID-19. *Cell* **183**, 1340-1353 e1316 (2020).
- 598 21. C. Havenar-Daughton *et al.*, Cytokine-Independent Detection of Antigen-Specific
599 Germinal Center T Follicular Helper Cells in Immunized Nonhuman Primates Using a
600 Live Cell Activation-Induced Marker Technique. *J Immunol* **197**, 994-1002 (2016).
- 601 22. J. Van Elslande *et al.*, Longitudinal follow-up of IgG anti-nucleocapsid antibodies in
602 SARS-CoV-2 infected patients up to eight months after infection. *J Clin Virol* **136**,
603 104765 (2021).
- 604 23. F. Muecksch *et al.*, Longitudinal Serological Analysis and Neutralizing Antibody Levels
605 in Coronavirus Disease 2019 Convalescent Patients. *J Infect Dis* **223**, 389-398 (2021).
- 606 24. A. Goubard *et al.*, Superantigenic *Yersinia pseudotuberculosis* induces the expression of
607 granzymes and perforin by CD4+ T cells. *Infect Immun* **83**, 2053-2064 (2015).
- 608 25. A. Sledzinska *et al.*, Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent
609 Acquisition of Cytotoxic Function by CD4(+) T Cells. *Immunity* **52**, 151-166 e156
610 (2020).
- 611 26. Y. Tian *et al.*, Unique phenotypes and clonal expansions of human CD4 effector memory
612 T cells re-expressing CD45RA. *Nat Commun* **8**, 1473 (2017).
- 613 27. T. E. Mockus, H. M. Ren, Shwetank, A. E. Lukacher, To Go or Stay: The Development,
614 Benefit, and Detriment of Tissue-Resident Memory CD8 T Cells during Central Nervous
615 System Viral Infections. *Viruses* **11**, (2019).
- 616 28. H. Chen *et al.*, Response of memory CD8+ T cells to severe acute respiratory syndrome
617 (SARS) coronavirus in recovered SARS patients and healthy individuals. *J Immunol* **175**,
618 591-598 (2005).

- 619 29. F. Krammer *et al.*, Antibody Responses in Seropositive Persons after a Single Dose of
620 SARS-CoV-2 mRNA Vaccine. *N Engl J Med* **384**, 1372-1374 (2021).
- 621 30. T. Dangi *et al.*, Cross-protective immunity following coronavirus vaccination and
622 coronavirus infection. *J Clin Invest*, (2021).
- 623 31. E. Mahase, Covid-19: What do we know about "long covid"? *BMJ* **370**, m2815 (2020).
- 624 32. J. L. Hirschtick *et al.*, Population-based estimates of post-acute sequelae of SARS-CoV-2
625 infection (PASC) prevalence and characteristics. *Clin Infect Dis*, (2021).
- 626 33. S. Havervall *et al.*, Symptoms and Functional Impairment Assessed 8 Months After Mild
627 COVID-19 Among Health Care Workers. *JAMA* **325**, 2015-2016 (2021).
- 628 34. D. Weiskopf *et al.*, Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-
629 19 patients with acute respiratory distress syndrome. *Sci Immunol* **5**, (2020).
- 630 35. L. B. Rodda *et al.*, Functional SARS-CoV-2-Specific Immune Memory Persists after
631 Mild COVID-19. *Cell* **184**, 169-183 e117 (2021).
- 632 36. T. Sekine *et al.*, Robust T Cell Immunity in Convalescent Individuals with Asymptomatic
633 or Mild COVID-19. *Cell* **183**, 158-168 e114 (2020).
- 634 37. S. Rasa *et al.*, Chronic viral infections in myalgic encephalomyelitis/chronic fatigue
635 syndrome (ME/CFS). *J Transl Med* **16**, 268 (2018).
- 636 38. M. Klingenstein *et al.*, Evidence of SARS-CoV2 Entry Protein ACE2 in the Human Nose
637 and Olfactory Bulb. *Cells Tissues Organs* **209**, 155-164 (2020).
- 638 39. E. Song *et al.*, Neuroinvasion of SARS-CoV-2 in human and mouse brain. *J Exp Med*
639 **218**, (2021).

- 640 40. T. Dangi, J. Class, N. Palacio, J. M. Richner, P. Penaloza MacMaster, Combining spike-
641 and nucleocapsid-based vaccines improves distal control of SARS-CoV-2. *Cell Rep* **36**,
642 109664 (2021).
- 643 41. J. Kantonen *et al.*, Neuropathologic features of four autopsied COVID-19 patients. *Brain*
644 *Pathol* **30**, 1012-1016 (2020).
- 645 42. M. Heming *et al.*, Neurological Manifestations of COVID-19 Feature T Cell Exhaustion
646 and Dedifferentiated Monocytes in Cerebrospinal Fluid. *Immunity* **54**, 164-175 e166
647 (2021).
- 648 43. E. Myasoedova, C. S. Crowson, H. M. Kremers, T. M. Therneau, S. E. Gabriel, Is the
649 incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-
650 2007. *Arthritis Rheum* **62**, 1576-1582 (2010).
- 651 44. E. F. Chakravarty, T. M. Bush, S. Manzi, A. E. Clarke, M. M. Ward, Prevalence of adult
652 systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained
653 using hospitalization data. *Arthritis Rheum* **56**, 2092-2094 (2007).
- 654 45. Z. Al-Aly, Y. Xie, B. Bowe, High-dimensional characterization of post-acute sequelae of
655 COVID-19. *Nature* **594**, 259-264 (2021).
- 656 46. A. J. Sant, A. T. DiPiazza, J. L. Nayak, A. Rattan, K. A. Richards, CD4 T cells in
657 protection from influenza virus: Viral antigen specificity and functional potential.
658 *Immunol Rev* **284**, 91-105 (2018).
- 659 47. A. E. Tebo *et al.*, Rapid recruitment of virus-specific CD8 T cells restructures
660 immunodominance during protective secondary responses. *J Virol* **79**, 12703-12713
661 (2005).

- 662 48. S. R. Crowe *et al.*, Differential antigen presentation regulates the changing patterns of
663 CD8+ T cell immunodominance in primary and secondary influenza virus infections. *J*
664 *Exp Med* **198**, 399-410 (2003).
- 665 49. S. E. Henrickson *et al.*, Antigen availability determines CD8(+) T cell-dendritic cell
666 interaction kinetics and memory fate decisions. *Immunity* **39**, 496-507 (2013).
- 667 50. G. Alter *et al.*, Immunogenicity of Ad26.COVS vaccine against SARS-CoV-2 variants
668 in humans. *Nature*, (2021).
- 669 51. D. D. Anthony *et al.*, Dissecting the T Cell Response: Proliferation Assays vs. Cytokine
670 Signatures by ELISPOT. *Cells* **1**, 127-140 (2012).
- 671 52. K. L. Good-Jacobson, M. J. Shlomchik, Plasticity and heterogeneity in the generation of
672 memory B cells and long-lived plasma cells: the influence of germinal center interactions
673 and dynamics. *J Immunol* **185**, 3117-3125 (2010).
- 674 53. D. Baumjohann *et al.*, Persistent antigen and germinal center B cells sustain T follicular
675 helper cell responses and phenotype. *Immunity* **38**, 596-605 (2013).
- 676 54. C. Bennisrallah *et al.*, Three COVID-19 cases with a long-term viral shedding period in
677 Tunisia. *Pan Afr Med J* **35**, 117 (2020).
- 678 55. T. L. Dao, V. T. Hoang, P. Gautret, Recurrence of SARS-CoV-2 viral RNA in recovered
679 COVID-19 patients: a narrative review. *Eur J Clin Microbiol Infect Dis* **40**, 13-25 (2021).
- 680 56. Y. Tian, L. Rong, W. Nian, Y. He, Review article: gastrointestinal features in COVID-19
681 and the possibility of faecal transmission. *Aliment Pharmacol Ther* **51**, 843-851 (2020).
- 682 57. A. S. van Doorn, B. Meijer, C. M. A. Frampton, M. L. Barclay, N. K. H. de Boer,
683 Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for
684 faecal-oral transmission. *Aliment Pharmacol Ther* **52**, 1276-1288 (2020).

- 685 58. Y. Chen *et al.*, The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. *J*
686 *Med Virol* **92**, 833-840 (2020).
- 687 59. R. Channappanavar, J. Zhao, S. Perlman, T cell-mediated immune response to respiratory
688 coronaviruses. *Immunol Res* **59**, 118-128 (2014).
- 689 60. S. N. Mueller, T. Gebhardt, F. R. Carbone, W. R. Heath, Memory T cell subsets,
690 migration patterns, and tissue residence. *Annu Rev Immunol* **31**, 137-161 (2013).
- 691 61. N. Palacio *et al.*, Early type I IFN blockade improves the efficacy of viral vaccines. *J Exp*
692 *Med* **217**, (2020).
- 693 62. E. J. Wherry, T cell exhaustion. *Nat Immunol* **12**, 492-499 (2011).
- 694 63. H. Shin, S. D. Blackburn, J. N. Blattman, E. J. Wherry, Viral antigen and extensive
695 division maintain virus-specific CD8 T cells during chronic infection. *J Exp Med* **204**,
696 941-949 (2007).
- 697 64. E. J. Wherry, D. L. Barber, S. M. Kaech, J. N. Blattman, R. Ahmed, Antigen-independent
698 memory CD8 T cells do not develop during chronic viral infection. *Proc Natl Acad Sci U*
699 *S A* **101**, 16004-16009 (2004).
- 700 65. Y. Tian *et al.*, Dengue-specific CD8+ T cell subsets display specialized transcriptomic
701 and TCR profiles. *J Clin Invest* **129**, 1727-1741 (2019).
- 702 66. E. Derhovanessian *et al.*, Infection with cytomegalovirus but not herpes simplex virus
703 induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in humans. *J*
704 *Gen Virol* **92**, 2746-2756 (2011).
- 705 67. F. R. Toapanta, P. J. Bernal, K. L. Kotloff, M. M. Levine, M. B. Sztein, T cell mediated
706 immunity induced by the live-attenuated *Shigella flexneri* 2a vaccine candidate CVD
707 1208S in humans. *J Transl Med* **16**, 61 (2018).

- 708 68. R. Karki *et al.*, COVID-19 cytokines and the hyperactive immune response: Synergism
709 of TNF-alpha and IFN-gamma in triggering inflammation, tissue damage, and death.
710 *bioRxiv*, (2020).
- 711 69. R. Karki *et al.*, Synergism of TNF-alpha and IFN-gamma Triggers Inflammatory Cell
712 Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock
713 Syndromes. *Cell* **184**, 149-168 e117 (2021).
- 714 70. S. F. Pedersen, Y. C. Ho, SARS-CoV-2: a storm is raging. *J Clin Invest* **130**, 2202-2205
715 (2020).
- 716 71. S. Diehl *et al.*, Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. *Immunity*
717 **13**, 805-815 (2000).
- 718 72. R. Channappanavar, S. Perlman, Pathogenic human coronavirus infections: causes and
719 consequences of cytokine storm and immunopathology. *Semin Immunopathol* **39**, 529-
720 539 (2017).
- 721 73. R. E. Sorge *et al.*, Different immune cells mediate mechanical pain hypersensitivity in
722 male and female mice. *Nat Neurosci* **18**, 1081-1083 (2015).
- 723 74. S. F. Rosen *et al.*, Increased pain sensitivity and decreased opioid analgesia in T-cell-
724 deficient mice and implications for sex differences. *Pain* **160**, 358-366 (2019).
- 725 75. D. R. Addis, J. J. DeBerry, S. Aggarwal, Chronic Pain in HIV. *Mol Pain* **16**,
726 1744806920927276 (2020).
- 727 76. H. I. Kemp, E. Corner, L. A. Colvin, Chronic pain after COVID-19: implications for
728 rehabilitation. *Br J Anaesth* **125**, 436-440 (2020).
- 729 77. T. Wang *et al.*, Transcriptomic profiling of peripheral blood CD4(+) T-cells in asthmatics
730 with and without depression. *Gene* **565**, 282-287 (2015).

- 731 78. A. H. Miller, Depression and immunity: a role for T cells? *Brain Behav Immun* **24**, 1-8
732 (2010).
- 733 79. C. Garber *et al.*, T cells promote microglia-mediated synaptic elimination and cognitive
734 dysfunction during recovery from neuropathogenic flaviviruses. *Nat Neurosci* **22**, 1276-
735 1288 (2019).
- 736 80. U. Sahin *et al.*, COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell
737 responses. *Nature* **586**, 594-599 (2020).
- 738 81. V. Oberhardt *et al.*, Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2
739 mRNA vaccine. *Nature* **597**, 268-273 (2021).
- 740 82. J. S. Lai *et al.*, How item banks and their application can influence measurement practice
741 in rehabilitation medicine: a PROMIS fatigue item bank example. *Arch Phys Med*
742 *Rehabil* **92**, S20-27 (2011).
- 743 83. M. Roederer, J. L. Nozzi, M. C. Nason, SPICE: exploration and analysis of post-
744 cytometric complex multivariate datasets. *Cytometry A* **79**, 167-174 (2011).
- 745 84. P. A. Harris *et al.*, Research electronic data capture (REDCap)--a metadata-driven
746 methodology and workflow process for providing translational research informatics
747 support. *J Biomed Inform* **42**, 377-381 (2009).




Figure 1

748 **Figure 1: Study design and clinical data**

749 A.) Flow chart describing study populations and experimental assays for each sample. B.) Table
750 showing subject demographics and neurologic symptoms. C.) PROMIS-57 patient-reported
751 survey T scores for Neuro-PASC (NP; n=36) and COVID convalescents (CC; n=13) groups. D.)
752 NIH Toolbox cognitive T scores for NP (n=43). Horizontal black line represents the U.S.
753 national average T score of 50; *p* values relative to US national average by one sample Wilcoxon
754 signed rank test. **p*<0.05, ****p*<0.005, *****p*<0.0001 by two-tailed Student's *t* test.




Figure 2

755 **Figure 2: Figure 2: Neuro-PASC reactivity to SARS-CoV-2 N and M peptides compared to**
756 **healthy COVID convalescents**

757 A-B.) NP (PCR+ or seropositive Neuro-PASC) and CC (PCR+ or seropositive healthy COVID
758 convalescent) groups display similar IFN- γ and IL-2 responses to peptides from SARS-CoV-2
759 Spike protein by ELISPOT. C-D.) NP samples show significantly enhanced IFN- γ responses to
760 the N3 peptide pool (C) and to the M1 and M3 peptide pools (D) compared with CC or HC. E-
761 F.) N- and M- specific IL-2 production did not significantly differ between subject groups. G.)
762 Spike RBD IgG endpoint titer quantification for NP, CC, and HC groups. *LOD* = limit of
763 detection. Data representative of 10 experiments with all conditions plated in duplicate. * $p < 0.05$,
764 ** $p < 0.01$, *** $p < 0.005$, **** $p < 0.0001$ by two-way ANOVA with Tukey's posttest.




Figure 3

765 **Figure 3: Tfh cell activation and CD4⁺ T cell polyfunctionality in response to SARS-CoV-2**
766 **structural proteins in Neuro-PASC**

767 A.) FACS plots showing that Ag-specific CD4⁺ Tfh from NP patients are more highly activated
768 in response to N peptide pool stimulation compared with CC, but less activated by Spike
769 peptides. B.) Quantification of AIM⁺ Tfh cell activation to S, N, and M peptides. C.) Anti-
770 SARS-CoV-2 Nucleocapsid IgG endpoint titers for NP, CC, and HC subjects shown in 3B. NP
771 patients display significantly elevated anti-N IgG titers compared with CC subjects. D.) CD4⁺ T
772 cells from NP produce significantly less IL-6 and TNF- α in response to N pool stimulation
773 compared with CC individuals. E.) Quantification of cytokine production from D. F.) CD4⁺ T
774 cells from NP subjects have enhanced polyfunctionality and granzyme production after S3/4
775 peptide stimulation compared with CC subjects. G.) Pie graphs show CD4⁺ T cells from CC
776 subjects have enhanced production of granzymes A & B, granzyme B & IL-6, and TNF- α & IL-6
777 compared with NP subjects in response to SARS-CoV-2 S3/4 pool stimulation. H.) Heatmap
778 quantifying polyfunctionality in different categories of cytokine production between groups. NP
779 subjects produced 2-fold more granzymes A/B/M than CC. Data combined from 6 independent
780 experiments with NP n=34, CC n=11. *p<0.05, **p<0.01, ***p<0.005 using one-way ANOVA
781 with Bonferroni's posttest (B, C); two-tailed Student's t Test with Welch's correction (E, F) or a
782 Permutation test (G). All pie graphs are showing data after subtracting background (unstimulated
783 condition; Fig. S6A).




Figure 4

784 **Figure 4: CD8⁺ memory T cell activation and function in Neuro-PASC**

785 A.) Selected FACS plots showing CD8 TEM cells are less activated in NP vs. CC groups after S
786 and N peptide pool stimulation. B.) Quantification of AIM⁺ CD8 TEM cells after S, N, and M
787 peptide stimulation. C.) CD8⁺ TEMRA cells accumulate significantly in PBMC from NP
788 subjects compared with CC or HC. D.) CD8⁺ TEMRA cells from NP patients are less activated
789 by S3/4 and N pools compared with those from CC subjects. E.) Quantification of AIM⁺ CD8⁺
790 TEMRA cells from D. F-G.) CD8⁺ TEM from NP have significantly enhanced IL-6 production
791 after S3/4 stimulation compared with CC. H.) Pie charts demonstrating that S3/4-specific CD8⁺
792 TEM are polarized to produce more TNF- α or granzyme B in CC group while those from NP
793 patients produce significantly more IL-6 and Perforin. I.) CD8⁺ TEMRA from NP patients have
794 elevated granzyme and Perforin production after S3/4 stimulation compared to CC subjects. J.)
795 CD8⁺ TEMRA from CC subjects are less polyfunctional in response to S3/4 stimulation
796 compared with NP subjects. Data combined from 5 independent experiments with n=34 NP,
797 n=11 CC. *p<0.05, **p<0.01 using two-tailed Student's t test with Welch's correction (B, C, E,
798 G, I) or Permutation test (H, J). All pie graphs are showing data after subtracting background
799 (unstimulated condition; Fig. S6 B-C).





Figure 5

800 **Figure 5: Correlation of psycho-cognitive clinical measures with CD8⁺ T cell function in**
801 **Neuro-PASC**

802 A.) Higher T cell responses to N pool stimulation are positively correlated with high pain scores
803 in NP patients. B.) A positive trend exists between elevated N-specific IFN- γ production and
804 higher depression scores in NP patients. C.) NP patients scoring high on pain interference have
805 Spike-specific CD8⁺ T cells producing more IL-6 than those scoring low. D.) Heatmap showing
806 NP with low pain scores have Spike-specific CD8⁺ T cells producing significantly more
807 granzymes A or B than those reporting high pain levels. E.) Pie graph to demonstrate that NP
808 patients in Q4 for depression have significantly enhanced production of granzymes A/B/M
809 compared with patients with low depression scores. F.) Heatmap demonstrating that NP patients
810 with high depression scores had Spike-specific CD8⁺ TEM producing 3-fold higher levels of
811 granzymes A, B, and M or Perforin than those scoring low on depression. G.) Spike-specific
812 CD8⁺ TCM from NP patients with high scores for executive function are more polarized to
813 produce granzymes A/B/M compared with NP patients from Q1. H.) Heatmap showing Spike-
814 specific CD8⁺ TCM in Q1 NP patients are more polyfunctional and produce 8-10x more
815 granzymes A/B/M and Perforin than those in Q4. Data representative of 5 independent
816 experiments with n=8-9/quartile. All pie graphs showing Ag-specific cytokine production are
817 background subtracted (unstimulated conditions). *p<0.05, **p<0.01, ****p<0.001 using
818 Permutation tests.


A.



B.

Vaccine Study Demographics	NP	CC	HC
Participants	19	12	20
Mean Age (range)	50.8 (33-70)	29.2 (22-63)	29.9 (22-59)
Sex	13F, 6M	7F, 5M	13F, 7M
Race/Ethnicity	12 White 5 Hispanic 1 Asian 1 Black	8 White 1 Hispanic 3 Asian	8 White 4 Hispanic 7 Asian 1 Black
Vaccine Brand	13 Pfizer 6 Moderna	10 Pfizer 2 Moderna	16 Pfizer 4 Moderna

C.



D.




Figure 6

819 **Figure 6: Spike-specific T cell and antibody responses after vaccination in Neuro-PASC**
820 **and COVID convalescents**

821 A.) Vaccine study visit timeline. V0 was obtained before the first dose of either Pfizer or
822 Moderna mRNA vaccines. V1 and V2 were conducted 3 weeks after the first and second doses,
823 respectively. B.) Vaccine study subject demographics. C.) IFN- γ production from Spike-specific
824 T cells do not significantly increase in CC and HC groups while remaining high in NP at 4
825 months post-vaccination. Total S-specific IFN- γ SFU calculated by averaging responses from
826 each sub-pool for each participant (data in Fig. S9). D.) Longitudinal anti-Spike RBD IgG
827 responses from V0-V4 across groups. Antibody titers are highest in NP patients at V2 and wane
828 most quickly in HC subjects. Titers were not significantly different pre-vaccination (V0)
829 between NP and CC individuals. Data combined from 10 individual experiments with all ELISA
830 conditions done in triplicate and all ELISPOT conditions plated in duplicate. * $p < 0.05$, ** $p < 0.01$,
831 *** $p < 0.005$, **** $p < 0.0001$ by two-way ANOVA with Tukey's posttest or by two-tailed
832 Student's t test.